Kaolin-induced chronic hydrocephalus accelerates amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP

Hakim S, Adams RD: The special clinical problem of symptomatic hydrocephalus with normal cerebrospinal fluid pressure. Observations on cerebrospinal fluid hydrodynamics.J Neurol Sci 1965, 2:307–27. 10.1016/0022-510X(65)90016-X

Symon L, Dorsch NW: Use of long-term intracranial pressure measurement to assess hydrocephalic patients prior to shunt surgery.J Neurosurg 1975, 42:258–73. 10.3171/jns.1975.42.3.0258

Symon L, Dorsch NW, Stephens RJ: Pressure waves in so-called low-pressure hydrocephalus.Lancet 1977, 2:1291–2.

Krauss JK, Droste DW, Bohus M, Regel JP, Scheremet R, Riemann D, et al.: The relation of intracranial pressure B-waves to different sleep stages in patients with suspected normal pressure hydrocephalus.Acta Neurochir (Wien) 1995, 136:195–203. 10.1007/BF01410626

Wikkelsø C, Hellström P, Klinge PM, Tans JT, European iNPH Multicentre Study Group: The European iNPH Multicentre Study on the predictive values of resistance to CSF outflow and the CSF Tap Test in patients with idiopathic normal pressure hydrocephalus.J Neurol Neurosurg Psychiatry 2013, 84:562–8. 10.1136/jnnp-2012-303314

Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D: Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis.Lancet Neurol 2003, 2:506–11. 10.1016/S1474-4422(03)00487-3

Silverberg GD: Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both.Brain 2004, 127:947–8. 10.1093/brain/awh178

Tullberg M, Hultin L, Ekholm S, Månsson JE, Fredman P, Wikkelsø C: White matter changes in normal pressure hydrocephalus and Binswanger disease: specificity, predictive value and correlations to axonal degeneration and demyelination.Acta Neurol Scand 2002, 105:417–26. 10.1034/j.1600-0404.2002.01189.x

Bateman GA: The pathophysiology of idiopathic normal pressure hydrocephalus: cerebral ischemia or altered venous hemodynamics?Am J Neuroradiol 2008, 29:198–203. 10.3174/ajnr.A0739

Del Bigio MR, Cardoso ER, Halliday WC: Neuropathological changes in chronic adult hydrocephalus: cortical biopsies and autopsy findings.Can J Neurol Sci 1997, 24:121–6.

Savolainen S, Paljärvi L, Vapalahti M: Prevalence of Alzheimer’s disease in patients investigated for presumed normal pressure hydrocephalus: a clinical and neuropathological study.Acta Neurochir (Wien) 1999, 141:849–53. 10.1007/s007010050386

Golomb J, Wisoff J, Miller DC, Boksay I, Kluger A, Weiner H, et al.: Alzheimer’s disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response.J Neurol Neurosurg Psychiatry 2000, 68:778–81. 10.1136/jnnp.68.6.778

Association A’s: Alzheimer’s disease facts and figures.Alzheimers Dement 2014,2014(10):e47–92.

Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes.Acta Neuropathol 1991, 82:239–59. 10.1007/BF00308809

The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease: Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease.Neurobiol Aging 1997,18(4 suppl):S1–2.

Selkoe DJ: Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.Ann NY Acad Sci 2000, 924:17–25.

Hardy J: A hundred years of Alzheimer’s disease research.Neuron 2006, 52:3–13. 10.1016/j.neuron.2006.09.016

Mawuenyega KG, Sigurdson W, Ovod V, Munselli T, Kasten T, Morris JC, et al.: Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease.Science 2010, 330:1774. 10.1126/science.1197623

Klinge PM, Samii A, Niesken S, Brinker T, Silverberg GD: Brain amyloid accumulation in aged rats with kaolin-induced hydrocephalus.NeuroReport 2006, 17:657–60. 10.1097/00001756-200604240-00020

Silverberg GD, Miller MC, Machan JT, Johanson CE, Caralopoulos IN, Pascale CL, et al.: Amyloid and Tau accumulate in the brains of aged hydrocephalic rats.Brain Res 2010, 1317:286–96.

Agca C, Fritz JJ, Walker LC, Levey AI, Chan AWS, Lah JJ, et al.: Development of transgenic rats producing human β-amyloid precursor protein as a model for Alzheimer’s disease: Transgene and endogenous APP genes are regulated tissue-specifically.BMC Neurosci 2008, 9:28. 10.1186/1471-2202-9-28

Klinge PM, Samii A, Muhlendyck A, Visnyei K, Meyer GJ, Walter GF, et al.: Cerebral hypoperfusion and delayed hippocampal response after induction of adult kaolin hydrocephalus.Stroke 2003, 34:193–9. 10.1161/01.STR.0000048820.17198.15

Masson PJ: Trichrome stainings and their preliminary techniques.J Tech Meth 1929, 12:75.

Luna L: Manual of histological staining methods of the armed forces insitiute of pathology. 3rd edition. New York: McGraw Hill; 1968:76–95.

Carson F: Histotechnology: a self-instructional text. 1st edition. Chicago: American Society for Clinical Pathology Press; 1990:142–9.

Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, et al.: Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation.J Biol Chem 1998, 273:32730–8. 10.1074/jbc.273.49.32730

Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al.: Identification of the major Abeta1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition.Nat Med 2000, 6:143–50. 10.1038/72237

Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al.: Metabolic regulation of brain Abeta by neprilysin.Science 2001, 292:1550–2. 10.1126/science.1059946

Kanemitsu H, Tomiyama T, Mori H: Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form.Neurosci Lett 2003, 350:113–6. 10.1016/S0304-3940(03)00898-X

Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B: Clearance of amyloid beta-peptide from brain: transport or metabolism?Nat Med 2000, 6:718–9.

Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al.: Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier.J Clin Invest 2000, 106:1489–99. 10.1172/JCI10498

Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, et al.: RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain.Nat Med 2003, 9:907–13. 10.1038/nm890

Deane R, Zlokovic BV: Role of the blood–brain barrier in the pathogenesis of Alzheimer’s disease.Curr Alzheimer Res 2007, 4:191–7. 10.2174/156720507780362245

Zlokovic BV: Clearing amyloid through the blood–brain barrier.J Neurochem 2004, 89:807–11. 10.1111/j.1471-4159.2004.02385.x

Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE, et al.: Amyloid deposition and influx transporter expression at the blood–brain barrier increase in normal aging.J Neuropathol Exp Neurol 2010, 69:98–108. 10.1097/NEN.0b013e3181c8ad2f

Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar S, Stopa EG, et al.: Amyloid efflux transporter expression at the blood–brain barrier declines in normal aging.J Neuropathol Exp Neurol 2010, 69:1034–43. 10.1097/NEN.0b013e3181f46e25

Pascale CL, Miller MC, Chiu C, Boylan M, Caralopoulos IN, Gonzalez L, et al.: Amyloid-beta transporter expression at the blood-cerebrospinal fluid barrier is age-dependent.Fluids Barriers CNS 2011, 8:21. 10.1186/2045-8118-8-21

Davson H, Oldendorf WH: Symposium on membrane transport. Transport in the central nervous system.Proc R Soc Med 1967, 60:326–9.

Oldendorf WH, Davson H: Brain extracellular space and the sink action of cerebrospinal fluid. Measurement of rabbit brain extracellular space using sucrose labeled with carbon 14.Arch Neurol 1967, 17:196–205. 10.1001/archneur.1967.00470260086010

Rennels ML, Blaumanis OR, Grady PA: Rapid solute transport throughout the brain via paravascular fluid pathways.Adv Neurol 1990, 52:431–9.

Johanson CE: Ventricles and Cerebrospinal fluid. In Neuroscience in Medicine. Edited by: Conn PM. Philadelphia: J.B. Lippincott Company; 1995:171–96.

Chiu C, Miller MC, Caralopoulos IN, Worden MS, Brinker T, Gordon ZN, et al.: Temporal course of cerebrospinal fluid dynamics and amyloid accumulation in the aging rat brain from three to thirty months.Fluids Barriers CNS 2012, 9:3. 10.1186/2045-8118-9-3

Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, Bronte-Stewart H, et al.: The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer’s type.Neurology 2001, 57:1763–6. 10.1212/WNL.57.10.1763

Silverberg GD, Huhn S, Jaffe RA, Chang SD, Saul T, Heit G, et al.: Downregulation of cerebrospinal fluid production in patients with chronic hydrocephalus.J Neurosurg 2002, 97:1271–5. 10.3171/jns.2002.97.6.1271

Hochwald GM, Nakamura S, Camins MB: The rat in experimental obstructive hydrocephalus.Z Kinderchir 1981, 34:403–10.

Hochwald GM, Sahar A: Effect of spinal fluid pressure on cerebrospinal fluid formation.Exp Neurol 1971, 32:30–40. 10.1016/0014-4886(71)90162-2

Brinker T, Beck H, Klinge P, Kischnik B, Oi S, Samii M: Sinusoidal intrathecal infusion for assessment of CSF dynamics in kaolin-induced hydrocephalus.Acta Neurochir (Wien) 1998, 140:1069–75. 10.1007/s007010050216

Kondziella D, Ludemann W, Brinker T, Sletvold O, Sonnewald U: Alterations in brain metabolism, CNS morphology and CSF dynamics in adult rats with kaolin-induced hydrocephalus.Brain Res 2002, 927:35–41. 10.1016/S0006-8993(01)03320-0

Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, et al.: Exogenous seeding of cerebral β-amyloid deposition in βAPP-transgenic rats.J Neurochem 2012, 120:660–6. 10.1111/j.1471-4159.2011.07551.x

Weller RO, Subash M, Preston SD, Mazanti I, Carare RO: Perivascular drainage of amyloid-beta peptides from thebrain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease.Brain Pathol 2008, 18:253–66.

Carare RO, Hawkes CA, Jeffrey M, Kalaria RN, Weller RO: Cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination-failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy.Neuropathol Appl Neurobiol 2013, 39:593–611. 10.1111/nan.12042